STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2815 by analyst upside · 2026-06-29
JAZZ
Jazz Pharmaceuticals plc
Healthcare · Market Cap $14B · P/E 1916.8x
ANALYST PRICE TARGET
+11.7%
implied upside to consensus target
Current Price $230.02
Consensus Target $257.0
Bull Target $307.0
Bear Target $196.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
11
Hold
2
Sell
0
52-Week Low $105.0
52-Week High $243.32
YTD Return +32.8%
FUNDAMENTALS
Market Cap $14B
P/E Ratio (TTM) 1916.8x
Forward P/E 9.0x
EPS (TTM) $0.12
PEG Ratio 0.96
Dividend Yield N/A
Revenue (TTM) $4.4B
Profit Margin 0.7%
52-WEEK RANGE
52-Week Low $105.0
52-Week High $243.32
Current Price $230.02
Bear Target $196.0
Bull Target $307.0
● Now $230.02 ● Target $257.0
TRADING DATA
Avg Volume 934K
YTD Return +32.8%
Analyst Count 19
Consensus Buy
Upside to Target +11.7%
Last Updated 2026-06-29

ANALYST SUMMARY

Jazz Pharmaceuticals plc (JAZZ) is currently trading at $230.02 with a Wall Street consensus price target of $257.0, implying potential upside of 11.7% over the next 12 months. 19 analysts currently cover JAZZ, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $307.0, while the most cautious has a target of $196.0.

JAZZ operates in the Healthcare sector with a market capitalisation of $14B. The stock is up 32.8% year-to-date and is currently trading near the upper end of its 52-week range of $105.0 – $243.32.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JAZZ, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities — Reiterated
Buy → Buy 2026-06-10 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-05-27 Building track record
Bernstein ● Initiated
Market Perform 2026-05-22 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-22 14% win rate (7 calls)
UBS ↑ Upgrade
Neutral → Buy 2026-05-19 33% win rate (6 calls)
TD Cowen — Reiterated
Buy → Buy 2026-05-06 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-06 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-05-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
23/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →